Sellas Life Sciences: Bankers Take the Full Green Shoe as REGAL Data Underpin the Raise
Published on 11/21/2026 at 06:30 | Editorial boerse-global.deSellas Life Sciences has closed the books on a share sale that bankrolled its balance sheet while testing its share price. The biotech confirmed that its syndicate of banks exercised the overallotment option in full, lifting the total placement to roughly 13.3 million shares and gross proceeds to $172.5 million before fees and expenses.
The mechanics were set in motion midweek, when Sellas priced the new stock at $13.00 per share. What began as an announced gross offering of $150.0 million grew once the greenshoe — covering up to 1,730,769 additional shares — was taken up entirely. Those extra shares, about 1.73 million in all, are folded into the final tally of the completed placement.
Net proceeds are expected to land at approximately $161.8 million after underwriting discounts, commissions and estimated costs. Completion of the transaction is anticipated today or thereabouts, subject to customary closing conditions, according to the company's mandatory disclosure.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
Equity holders, meanwhile, marked the stock down. Shares shed 8.1% in the prior session to close at €12.45, and were off a further 7.4% at €12.55 in the latest trading — a retreat that tracks the discounted pricing of the new stock rather than any shift in the company's prospects.
The capital raise follows hard on the heels of a clinical catalyst. On November 17, Sellas reported positive topline results from the Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia. The study hit its primary endpoint on overall survival: median OS reached 24.0 months on galinpepimut-S versus 14.7 months for the best available treatment, a 41% reduction in the risk of death.
The statistical readout was equally supportive. Sellas put the hazard ratio at 0.59 and the p-value at 0.035. With those numbers in hand, the company intends to open talks with the FDA on a pathway toward an accelerated submission and to push ahead with preparations for a marketing application.
Ad
Sellas Life Sciences Stock: New Analysis - 21 November
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
